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Background  and  aims:  In  Germany,  a mandatory  early  beneﬁt  assessment  (EBA)  by the Fed-
eral Joint  Committee  (G-BA)  is required  for  reimbursement  of new  marketing-authorised
medicines.  Additional  beneﬁt  is based  on  patient-relevant  endpoints  in  mortality,  morbid-
ity  and  health-related  quality  of  life  (HRQoL).  We  aimed  to  compare  endpoints  and  related
beneﬁt categories  used  in  marketing  authorisation  to  those  considered  by G-BA  in  the  ﬁeld
of oncology.
Methods:  We  evaluated  EBAs  in oncology  commencing  prior  to  31 December  2013. End-
points for  the appropriate  medicines,  derived  from  European  Medicines  Agency’s  (EMA)
Summary  of  Product  Characteristics  (SPC),  manufacturers’  value  dossiers  and  G-BA  deci-
sions,  were  grouped  into  the  three  beneﬁt  categories.
Results: Of  23 oncology  medicines  evaluated,  primary  clinical  trial endpoints  were  included
in only 12  G-BA  value  decisions.  Mortality  endpoints  were  generally  accepted  by EMA
and G-BA.  However,  G-BA  excluded  80%  of (co-)primary  morbidity  endpoints.  Only  5 SPCs
reported  HRQoL  instruments.  G-BA  accepted  applied  instruments  in  15  medicines,  but the
manufacturers’  analyses  only  in 5 medicines,  of which  2 indicated  an  additional  beneﬁt.
Conclusions:  Mortality  endpoints  are  accepted  by EMA  and  G-BA.  EMA  accepted  well
established  and  clinically  relevant  morbidity  endpoints  (e.g.  progression-free  survival  and
response  rate),  which  were  mostly  excluded  by  G-BA  from  their  value  decisions.  The  appli-
cability of  methods  used  for beneﬁt  assessments  to HRQoL  differs  from  the  mortality  and
morbidity  categories,  and  requires  further  clariﬁcation.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B∗ Corresponding author at: Roche Pharma AG, Emil-Barrell-Strasse 1,
79639 Grenzach-Wyhlen, Germany. Tel.: +49 7624 143166;
fax: +49 7624 14 3208.
E-mail address: joerg.ruof@roche.com (J. Ruof).
http://dx.doi.org/10.1016/j.healthpol.2014.08.004
0168-8510/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Access to new medicines in Germany depends on mar-
keting authorisation from the European Medicines Agency
(EMA). Since the introduction of the Act on the Reform of
the Market for Medicinal Products (AMNOG) in January
2011, a demonstration of additional therapeutic beneﬁt
versus an appropriate comparator (AC) in the form of an
early beneﬁt assessment (EBA) is mandatory for all new
is is an open access article under the CC BY-NC-ND license
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edicines. The EBA is conducted as a two-step approach
y the Institute for Quality and Efﬁciency in Health Care
IQWiG) (scientiﬁc assessment) and the Federal Joint Com-
ittee (Gemeinsamer Bundesausschuss, G-BA) (appraisal)
1–3]. The G-BA ultimately decides the level of addi-
ional beneﬁt of a medicine, which in turn inﬂuences the
eimbursement by statutory health insurances (SHI) [3].
hereas a positive additional beneﬁt supports a negotiable
rice premium over the AC, medicines that receive no addi-
ional beneﬁt by the G-BA are priced no higher than the
rice of the comparator. Additional therapeutic beneﬁt is
ased on patient-relevant endpoints grouped into three
eneﬁt categories: mortality, morbidity and health-related
uality of life (HRQoL) [2–4].
The aims of the evaluation of the G-BA and the reg-
latory authorities clearly differ. The EMA  and other
egulatory agencies focus principally on efﬁcacy and safety
ata derived from clinical trials to decide on whether a
edicine should be licensed or not. The data are optimised
o demonstrate a positive beneﬁt–risk balance in a limited
ime period with high internal validity and minimal risk to
atients. Clinical trials usually evaluate the clinical effect
often based on a single primary endpoint) and safety of a
iven medicine in a limited number of patients. Instead, the
-BA evaluates the comparative value of a new medicine
ersus current standard of care derived from internal crite-
ia. However, the G-BA assesses and acts based on the same
alue dimensions (desirable effect [beneﬁt and value] and
arm [side effects and risks]). The marketing authorisation
rocess is well established, and manufacturers are able to
raw upon a wealth of guidance and experience in the con-
uct of clinical trials and acceptable clinical endpoints. In
ontrast to the current marketing authorisation process,
urrent practice relating to EBAs is being guided largely by
imited precedent and experience [5–7]. However, regula-
ory and health technology assessment (HTA) perspectives
ork from a comparable, given set of patient data.
Early evidence indicates that endpoints used to support
arketing authorisation are not necessarily included by
he G-BA in their value decision [6]. Demands on the manu-
acturers from the G-BA differ from those of the regulatory
uthorities in terms of acceptable endpoints.
In the case of oncology medicines, extensive oncology-
peciﬁc guidance and experience exist relating to accept-
ble oncology endpoints for marketing authorisation
8–10]. In contrast, as the G-BA guidance is not speciﬁc to
isease, there is no particular guidance on oncology end-
oints for EBAs. In oncology, clinical efﬁcacy is based on
urvival beneﬁt and measures of disease morbidity, such as
rogression-free survival (PFS), disease-free survival (DFS)
r overall response rate (ORR). The EMA  recommends cure
ate, overall survival (OS) and PFS/DFS as acceptable pri-
ary endpoints (Table 1) [8]. The EMA  and FDA guidelines
re generally consistent and agree that favourable effects
n survival are the most persuasive outcomes of a clinical
rial [8,9]. Each endpoint has its advantages and disadvan-
ages depending on the patient population and time-frame
f evaluation (Table 1).
In an attempt to further explore the interpretation of
dded value by the G-BA, we evaluated current value
ssessments in Germany for oncology medicines. We18 (2014) 242–254 243
compared endpoints and related beneﬁt categories applied
in regulatory trials supporting marketing authorisation to
those included in the value decisions of the G-BA.
2. Methods
We  evaluated oncology medicines that received mar-
keting authorisation and commenced EBA in Germany
between 1 January 2011 (the day AMNOG was  introduced)
and 31 December 2013. The G-BA website was used to
obtain the manufacturers’ value dossiers and the G-BA
value decisions [11]. We determined levels of additional
beneﬁt assigned by the G-BA according to their speciﬁed
ratings [2,3]: positive (category: major [1], considerable [2],
minor [3] or not quantiﬁable [4] additional beneﬁt) and
negative (category: no additional beneﬁt [5]/less beneﬁt
[6]). The G-BA assesses the additional beneﬁt for respective
subgroups of patients [12]. To allow for comprehensibility,
the additional beneﬁt decisions reported in this analysis
relate to the subgroup and the indication attaining the
highest level of beneﬁt. In case of a re-assessment, the more
recent assessment was  evaluated. The overall rating was
stated.
The Summary of Product Characteristics (SPC) was  used
as the data source for the respective marketing authorisa-
tions and was  derived from the website of the EMA. Clinical
trial endpoints that supported the marketing authorisa-
tion and the beneﬁt assessment were derived from (i) the
SPCs, (ii) manufacturers’ value dossiers and (iii) the G-BA
value decisions (underlying document: ‘Tragende Gründe’
and supporting material). According to the German Social
Law, the additional beneﬁt of a new medicine has to be
evaluated with respect to the three beneﬁt categories: mor-
tality, morbidity, and HRQoL (2–4). Any additional beneﬁt
is considered in combination with safety as a fourth beneﬁt
category. Therefore, derived endpoints from the three data
sources were grouped into those three beneﬁt categories.
The subsequent analysis included three steps:
1) Endpoints covering the beneﬁt category of mortality
were identiﬁed and acceptance of those endpoints by
both EMA  and G-BA was compared.
2) The same approach was  applied to endpoints covering
the beneﬁt category of morbidity. PFS was considered a
measure of oncology-related morbidity and was  there-
fore included in the beneﬁt category of morbidity.
3) HRQoL endpoints and supporting standardised assess-
ment instruments were identiﬁed. Acceptance of
respective instruments by the G-BA was explored as
well as methodological acceptance of the speciﬁc analy-
sis provided by the manufacturer and the consideration
of the content of the analysis as an element to support
additional beneﬁt for the medicine.
An additional comparison addressed the (co-)primary
clinical trial endpoints supporting marketing authorisa-
tion as reported in the SPC. All (co-)primary endpoints of
randomised controlled trials (if not available, studies with
other designs were considered) were assessed and their
inclusion in the G-BA value decision was determined.
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Table 1
Regulatory acceptance of endpoints for marketing authorisation of cancer medicines.
Endpoint Advantages [8,9] Disadvantages [8,9] Acceptance [8]
Mortality
Overall survival Universally accepted direct measure of
beneﬁt, precisely and easily measured
Large studies, long duration, affected by
cross-over and follow-up therapies,
includes non-cancer death
+++
Morbidity
Progression-free survival Smaller sample size and shorter follow-up
necessary compared with overall survival,
measurement of stable disease included,
not affected by cross-over or subsequent
therapies, generally based on objective and
quantitative assessments
Not validated as surrogate for survival in all
settings, not precisely measured; subject
to  assessment bias, not clearly deﬁned
+++
Time  to progression Useful in situations where the majority of
deaths are unrelated to cancer
Not validated as surrogate for survival in
all  settings, not precisely measured;
subject to assessment bias, not clearly
deﬁned, death is censored
++
Disease-free survival Smaller sample size and shorter follow-up
necessary compared with overall survival
Not validated as surrogate for survival in all
settings, not precisely measured; subject
to  assessment bias, not clearly deﬁned
+++
Event-free survival Useful in certain settings, e.g. small
populations; can support response data
Analysis requires sufﬁciently mature data;
confounded by consolidation/maintenance
therapy
++
Symptoms Patient perspective of direct clinical beneﬁt Data frequently missing or incomplete,
clinical signiﬁcance of small changes
unknown, lack of validated instruments
++
Overall response rate Assessed earlier and in smaller studies
compared with overall survival, effect
attributable to medicine, not natural
history
Not a direct measure of beneﬁt, not a
comprehensive measure of medicine
activity, only subset of patients who
beneﬁt
+
Complete response Durable complete responses can represent
clinical beneﬁt, assessed earlier and in
smaller studies compared with overall
survival
Not a direct measure of beneﬁt, not a
comprehensive measure of medicine
activity, small subset of patients with
beneﬁt
++
Cure  rate Convincingly demonstrated favourable
effects on survival are the most persuasive
outcome of a clinical trial
Due to the complexity of administered
therapies, the impact of an experimental
compound may  be hard to demonstrate
+++
Biomarkers Aids in understanding the
exposure–response relationships for the
medicine, may  allow for a rational
selection of treatment strategies
Biomarkers tested in early clinical trials
often exploratory in nature, essential to
assure technical/quantitative reliability;
careful and rigorous validation required
+
Health-related quality of life
Health-related quality of life Patient perspective, especially useful in
palliative setting
Data frequently missing or incomplete,
clinical signiﬁcance of small changes
unknown, poorly deﬁned prospective
analytic plans
+
point fo+++, generally accepted as primary endpoint; ++, accepted as primary end
endpoint.
3. Results
EBAs and respective marketing authorisations of 23
oncology medicines covering the time period of 1 January
2011 to 31 December 2013 were included in the analy-
sis. Table 2 shows the medicines assessed, the treatment
indication, the beneﬁt rating assigned by the G-BA, the pri-
mary endpoints within the supporting clinical trials and
the consideration of those endpoints by the G-BA.
3.1. Primary and co-primary endpoints
Seventeen of 23 medicines (74%) included only 1
primary endpoint in their supporting clinical trials; the
remaining 6 medicines (26%) included a co-primary
endpoint, or various primary endpoints in the different
pivotal studies. Two of 23 medicines (9%) included bothr special settings; +, accepted as secondary endpoint or part of composite
mortality and morbidity beneﬁt categories as primary and
co-primary endpoints.
The primary endpoint was included by the G-BA in 12
of 23 decisions (52%). The majority of accepted primary
endpoints demonstrated OS (Table 2).
In 10 of 23 medicines (44%), primary clinical trial end-
points were related to the beneﬁt category of mortality (i.e.
OS), which was generally accepted by both EMA  and G-BA
(Table 2). However, in tegafur/gimeracil/oteracil the phar-
maceutical manufacturer decided not to submit a complete
value dossier. In this case the G-BA judged the medicine to
be of ‘no additional beneﬁt’ without further comment on
the endpoint or the data that led to medicine approval. In 2
medicines (abiraterone acetate and vemurafenib), the pri-
mary and co-primary endpoints included both OS and PFS.
In both medicines, the G-BA accepted only the mortality
endpoint (OS) as relevant to patients.
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Table 2
Inclusion of primary endpoints from marketing authorisation in G-BA value decisions.
Medicine Indication G-BA beneﬁt
ratinga
Marketing authorisation
(primary endpoints)b
Inclusion of primary endpoint
in G-BA value decisionc
Explanatory comment
Abiraterone acetate Prostate cancer 2 OS and rPFS (co-primary
endpoints)
Yes G-BA decision based on OS data. rPFS was
disregarded by G-BA
Afatinib Non-small cell lung
carcinoma
2 PFS No Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
Aﬂibercept Colorectal cancer 3 OS Yes
Axitinib Renal cell carcinoma 3 PFS No Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
Bosutinib Chronic myelogenous
leukaemia
4 MCR  (Yes) Due to low event rate and lack of control arm,
MCR  was  not considered for beneﬁt decision.
Acceptance of endpoint remains questionable
Brentuximab vedotin Hodgkin’s lymphoma,
anaplastic large cell
lymphoma
4 ORR (CR + PR) No Deﬁnition of endpoint ORR was considered as
‘not relevant to patients’
Cabazitaxel Prostate cancer 3 OS Yes
Crizotinib Non-small cell lung
carcinoma
2 PFS, ORR No PFS: divergent opinions within G-BA; endpoint
had no inﬂuence on beneﬁt decision
ORR: deﬁnition considered as ‘not relevant to
patients’
Dabrafenib Melanoma 5 PFS, (OI)RR No Manufacturer provided indirect comparison
which was methodologically challenged by
G-BA. Regarding PFS, G-BA commented that
the endpoint was ‘not relevant to patients’
Decitabine Myeloid leukaemia 3 OS Yes
Enzalutamide Prostate cancer 2 OS Yes
Eribulin Breast cancer 3 OS Yes
Ipilimumab Melanoma 2 OS Yes
Pertuzumab Breast cancer 2 PFS, RR No PFS: divergent opinions within G-BA; endpoint
had no inﬂuence on beneﬁt decision
RR: deﬁnition considered as ‘not relevant to
patients’
Pixantrone Non-Hodgkin’s
lymphoma
5 RR Not applicable The comparator within the study was  not
accepted by G-BA. The applied endpoints were
not considered by G-BA
246
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Table 2 (Continued)
Medicine Indication G-BA beneﬁt
ratinga
Marketing authorisation
(primary endpoints)b
Inclusion of primary endpoint
in G-BA value decisionc
Explanatory comment
Pomalidomide Myeloma 2 PFS No Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
Ponatinib Chronic myeloid
leukaemia, acute
lymphoblastic
leukaemia
4 MCR, MHR (Yes) G-BA challenged the historical comparison and
the lack of a comparator group. Therefore, MCR
and MHR  were not considered for beneﬁt
decision. Acceptance of endpoints remains
questionable
Regorafenib Metastatic colorectal
cancer
3 OS Yes
Ruxolitinib Chronic
myeloproliferative
disorders
3 Number of patients with ≥35%
reduction in spleen volume in
Week 24
(Yes) G-BA accepts reduction in spleen volume if it is
related to a decrease in disease symptoms
Tegafur/gimeracil/oteracil Gastric cancer 5 OS Not applicable No complete dossier was provided by the
manufacturer. Therefore, no full beneﬁt
assessment was conducted by G-BA
Vandetanib Thyroid neoplasms 3 PFS No Divergent opinions within G-BA, however,
deﬁnition of endpoint was not considered
directly relevant to patients
Vemurafenib Melanoma 2 PFS and OS (co-primary
endpoints)
Yes G-BA decision based on OS data. PFS was
disregarded by G-BA
Vismodegib Basal cell carcinoma 3 ORR No Deﬁnition of endpoint was not accepted by
G-BA
CR, complete response; G-BA, Federal Joint Committee; MCR, major cytogenic response; MHR, major haematologic response; (O[I])RR, (overall [intracranial]) response rate; OS, overall survival; PR, partial
response; (r)PFS, (radiographic) progression-free survival.
a Overall score is stated. In case of different subgroups/indications for a medicine, the best subgroup/indication assessment is shown. In case of a re-assessment, the most recent assessment is shown. Positive
(category: major [1]; considerable [2]; minor [3]; not quantiﬁable [4] additional beneﬁt) and negative (category: no [5]/less [6] additional beneﬁt).
b A given marketing authorisation may  have included more than one trial or primary endpoint. Summary of Product Characteristics was used as a data source for randomised controlled trials (if not available,
studies  with other designs were considered) supporting marketing authorisation.
c Inclusion means that the G-BA in principle accepted endpoints as valid; however, it does not mean that the data led to a favourable beneﬁt assessment. Material for G-BA decision (decision, rationale ‘Tragende
Gründe’  and summary ‘Zusammenfassende Dokumentation’ [if available]) was  used as a data source.
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In 15 of 23 medicines (65%), (co-)primary clinical trial
ndpoints covered the beneﬁt category of morbidity, of
hich 12 endpoints (80%) were excluded by the G-BA
rom their value decision as being not patient relevant
Table 2). PFS was included as a (co-)primary endpoint
n 9 of 23 analysed trial programmes (39%). It was  dis-
ussed ambiguously in 6 of those programmes (afatinib,
xitinib, crizotinib, pertuzumab, pomalidomide and van-
etanib) but disregarded as not being relevant to patients
y the G-BA in 3 medicines.
Response rate (RR) was included as a (co-)primary end-
oint in 6 of 23 trial programmes but was never considered
s relevant to patients by the G-BA (Table 2).
The morbidity endpoint ‘major cytogenic response’ was
ncluded by the G-BA in 2 decisions (bosutinib, ponatinib)
s well as ‘major haematologic response’ in 1 decision
ponatinib). However, the acceptability of these endpoints
y G-BA remains questionable (Table 2).
The G-BA included the decrease in disease symptoms
s a morbidity endpoint in the EBA of ruxolitinib. This
ecrease was based on the reduction in spleen volume ana-
ysed as a primary endpoint in the marketing authorisation
rogramme. The correlation of reduction in spleen volume
nd decrease of disease symptoms was accepted by the
-BA.
.2. Mortality endpoints
In all marketing authorisation programmes of the 23
edicines, OS was used at least as a secondary endpoint. In
0 of these (44%), OS was a primary or co-primary endpoint
Table 2). In addition, in 6 of 23 evaluations (26%) the G-BA
ecision was based on OS results, derived as a secondary
ndpoint from the pivotal trials.
The manufacturer included OS data in G-BA submissions
f 22 medicines. The G-BA evaluated the beneﬁt cate-
ory of mortality in 20 of the 23 analysed EBAs (87%). For
he remaining 3 medicines (dabrafenib, pixantrone, tega-
ur/gimeracil/oteracil) no evaluation was performed, due
o missing or incomplete dossier submission [11]. For 15
f the 23 medicines (65%), an additional beneﬁt in OS was
onﬁrmed by the G-BA [11]. In 9 of 23 EBAs (39%), the deci-
ion on overall additional beneﬁt was based solely on the
ortality endpoint OS [11].
.3. Morbidity endpoints
For 15 of 23 medicines (65%), morbidity endpoints were
he primary clinical trial endpoints, and 12 were excluded
rom the G-BA value decision (80%) (Table 2). The man-
facturer claimed an effect on morbidity endpoints in 22
edicines. The beneﬁt category of morbidity was included
n 15 of the 23 analysed G-BA decisions (65%) (Table 3). An
dditional beneﬁt in morbidity was conﬁrmed for 10 of 23
BAs (44%) [11].
Considerable variability in endpoint acceptance was
ound in the beneﬁt category of morbidity between mar-
eting authorisation and G-BA assessment. Whereas the
umber of morbidity endpoints in the SPCs and the num-
er of morbidity endpoints claimed as patient-relevant
y the manufacturers in their dossiers were comparable18 (2014) 242–254 247
(both around 85), only 24 morbidity endpoints were eval-
uated by the G-BA (Table 3). In 7 medicines, where a
complete dossier was submitted by the manufacturer, none
of the morbidity endpoints presented in the dossier were
included in the G-BA value decision.
PFS was included in 21 marketing authorisation pro-
grammes for the 23 evaluated oncology medicines as
a primary (9 medicines) or secondary endpoint (12
medicines). PFS was generally excluded by the G-BA from
their value decisions. However, it was  acknowledged that
divergent opinions exist within the G-BA regarding the
patient relevance of PFS. Further, neither the opposing pos-
itions nor the rationales of the different views are provided
in the dossiers. In any case, the endpoint had no inﬂuence
on the decision of overall additional beneﬁt.
Response was included in 20 of 23 SPCs (87%) and in
the dossier of 17 of 23 medicines (74%) (Table 3). ORR
(including best overall response rate [BORR]) was  the most
frequently applied measure of response in the SPCs (14
medicines [BORR in 2 medicines]) followed by tumour
response and CR, which were used in 4 and 3 medicines,
respectively. In the dossiers, RR (including ORR) was used in
11 medicines (ORR in 9 medicines), CR in 4 medicines, and
tumour response in 3 medicines. The G-BA never included
RR and tumour response, but considered CR as relevant
in 2 medicines (brentuximab vedotin and decitabine) if it
was related to a decrease in symptoms. Major cytogenic,
haematologic and molecular responses were applied in 2
medicines (bosutinib, ponatinib); however, acceptability
by G-BA remains in question.
Improvements in disease severity (e.g. reduction in
symptoms or prolonged time to ﬁrst skeletal event) were
included in the SPCs and as a measure of morbidity in the
dossiers of 12 of 23 medicines (52%) (Table 3). The G-BA
considered these endpoints in 8 of the 12 medicines (67%).
Decrease in symptoms was the most frequently included
endpoint in 6 decisions. Other applied morbidity endpoints
indicating an improvement in disease severity are listed in
Table 3.
Pain was  included in 3 of 23 SPCs (13%) and applied as a
measure for morbidity in 5 of 23 medicines (22%), with con-
sideration by the G-BA in 3 of the 5 medicines (cabazitaxel,
vandetanib and vemurafenib) (Table 3).
Tolerability was  included as a morbidity endpoint in
3 of the 23 medicines (13%) and used by the G-BA in the
evaluation of ipilimumab (Table 3).
Disease-free survival (DFS) and event-free survival (EFS)
are widely accepted endpoints in market authorisation.
However, both were never or rarely used in the SPCs and
in the dossiers of the evaluated medicines to prove an
additional beneﬁt. While EFS was used in 2 medicines
(brentuximab vedotin and decitabine), DFS was not used
in any dossier (Table 3). However, EFS was not included by
the G-BA in any value decision.
Besides methodological issues preventing the eval-
uation of the overall additional beneﬁt (e.g. for the
dossiers of dabrafenib, eribulin, pixantrone and tega-
fur/gimeracil/oteracil), established and recognised clinical
trial endpoints for morbidity (e.g. PFS and ORR [8]) were not
included in the G-BA value decision due to lack of validation
and rationale for clarifying its patient relevance from the
248
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Table 3
Inclusion of morbidity endpoints of cancer medicines in G-BA value decision.
Medicine Morbidity endpoints in Summary of Product
Characteristics
Morbidity endpoints in manufacturer’s EBA
dossier
Morbidity endpoints included in G-BA value
decisiona
Abiraterone acetate Time to start of opiate therapy Time to start of opiate therapy Time to start of opiate therapy
Time  to start of cytotoxic chemotherapy Time to start of cytotoxic chemotherapy Time to ﬁrst skeletal event
Time  to ECOG-PS worsening Time to ECOG-PS worsening Time to pain progression
Time  to pain progression Time to pain progression
rPFS Pain reduction
Time to PSA progression rPFS
ORR Time to PSA progression
PSA response
Time to ﬁrst skeletal event
Fatigue
Afatinib PFS PFS Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decisionORR  ORR
Symptoms (EORTC QLQ-C30, QLQ-LC13) Symptoms (EORTC QLQ-C30, QLQ-LC13) Symptoms (EORTC QLQ-C30, QLQ-LC13)
Aﬂibercept PFS PFS None
ORR ORR
Axitinib PFS PFS Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decisionORR  ORR
Symptoms (FKSI–DRS score; endpoint
classiﬁed as HRQoL by manufacturer)
Bosutinib Transition to accelerated phase or blast crisis Transformation into accelerated phase or blast
crisis
MCR,  MHR, MMR  MCR, MHR, MMR  Acceptance of MCR, MHR, MMR  questionable
PFS  PFS PFS was disregarded by G-BA
Brentuximab vedotin BORRb Proportion of patients achieving CR CR if related to decrease in patient symptoms
Decrease of B symptoms Decrease of B symptoms Decrease of B symptoms
PFS  Surrogate endpoints: ORR, PFS, EFS
DCR
Response duration
Cabazitaxel Change in PPI score (pain) Change in PPI score (pain) Change in PPI score (pain)
PSA  progression Tumour progression
PFS Surrogate endpoints: PFS, proportion of
patients achieving PSA decline
PSA response
Tumour response rate
Pain progression
Crizotinib ORR ORR Symptoms (EORTC QLQ-C30, QLQ-LC13)
PFS  PFS
Time to tumour response Time to tumour response
Duration of response Duration of response
DCR DCR
Dabrafenib Tumour response Tumour response Symptoms (EORTC QLQ-C30)
PFS  PFS
OIRR/ORR
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Decitabine CR/CRp CR/CRp CR if related to decrease in patient symptoms
PFS  PFS
EFS EFS
Duration CR/CRp
Transfusion independency
Overall response
Time in hospital
Enzalutamide PSA progression
rPFS rPFS
Time to ﬁrst skeletal event Time to ﬁrst skeletal event Time to ﬁrst skeletal event
Pain  (TWP, rate of worsening of pain, change in
pain intensity)
TWP
Paralysis, paralysis dependant urinary
incontinence
Change in pain intensity
Eribulin PFS Tolerability None
ORR
Ipilimumab BORRb None
DCR
Tolerability (therapy-dependent morbidity) Tolerability evaluated as a safety endpoint
Pertuzumab PFS PFS Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
ORR  ORR
pCR
Response duration
Pixantrone CR/CRu CR The comparator within the study was  not
accepted by G-BA. The applied endpoints were
not considered by G-BA
ORR
PFS  PFS
Pomalidomide PFS PFS Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
Duration of PFS
TTP
RR (CR, VGPR, PR)
Clinical response (improvement of bone pain,
ECOG-PS)
Ponatinib MCR, MHR, MMR  MCR, MHR, MMR  Acceptance of MCR, MHR, MMR  questionable
Duration of response Duration of response
Time to response Time to response
PFS  PFS
Regorafenib PFS PFS (as combined endpoint for mortality and
morbidity)
Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
DCR  DCR
Tumour response Tumour response (duration of tumour
stability)
ORR
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Table 3 (Continued)
Medicine Morbidity endpoints in Summary of Product
Characteristics
Morbidity endpoints in manufacturer’s EBA
dossier
Morbidity endpoints included in G-BA value
decisiona
Ruxolitinib Change in spleen size Change in spleen size
Maintenance of change in spleen size
Reduction in symptoms Reduction in symptoms Reduction in symptoms
Leukaemia-free survival
Tegafur/gimeracil/oteracil PFS No complete dossier submitted No complete dossier was provided by the
manufacturer. Therefore no full beneﬁt
assessment was conducted by G-BA
Tumour response
Vandetanib PFS PFS Divergent opinions within G-BA; endpoint had
no inﬂuence on beneﬁt decision
TWP  TWP  (BPI-SF and opiate use) TWP (BPI-SF and opiate use)
ORR  ORR
Duration of response Duration of response
DCR DCR
Weight gain
Impact on diarrhoea
WHO  performance status
Biochemical response Surrogate parameter: Biochemical response
Vemurafenib PFS PFS
ORR Response (rate, duration, time to response)
Pain (visual analogue scale) Pain (visual analogue scale)
Tolerability
Vismodegib ORR ORR  Reduction in size of externally visible tumour
and related ulceration considered relevant to
patients
PFS  PFS
Duration of response
Decrease of target lesion size
BCS, best supportive care; BORR, best overall response rate; BPI-SF, Brief Pain Inventory Short Form; (p)CR, (pathological) complete response; CRp, complete response with incomplete blood count recovery; CRu,
unconﬁrmed complete response; DCR, disease control rate; ECOG-PS, Eastern Cooperative Oncology Group Performance Score; EBA, early beneﬁt assessment; EORTC-QLQ, European Organisation for Research and
Treatment  of Cancer Quality of Life Questionnaire (C, cancer; LC, lung cancer); EFS, event-free survival; G-BA, Federal Joint Committee; HRQoL, health-related quality of life; MCR, major cytogenic response; MHR,
major  haematologic response; MMR,  major molecular response; (O[I])RR, (overall [intracranial]) response rate; (r)PFS, (radiographic) progression-free survival; PPI, present pain intensity; PSA, prostate-speciﬁc
antigen;  RR, response rate; TTP, time to progression; TWP, time to worsening of pain; VGPR, very good partial response; WHO, World Health Organisation.
a Inclusion means that the G-BA in principle accepted endpoints as valid; however, it does not mean that the data led to a favourable beneﬁt assessment. Material for G-BA decision (decision, rationale ‘Tragende
Gründe’  and summary ‘Zusammenfassende Dokumentation’ [if available]) was  used as data source.
b (B)ORR reported to include CR and PR.
 Policy 1
p
i
r
o
3
5
m
H
s
t
i
(
m
‘
c
w
m
o
s
A
w
Q
i
H
m
v
f
s
[
a
i
i
G
i
m
4
m
i
G
1
2
3
e
a
uJ. Ruof et al. / Health
erspective of the G-BA (Table 2). Although improvements
n disease severity and pain were considered patient-
elevant morbidity endpoints, the G-BA did not support PFS
r RR as being patient relevance (Table 3).
.4. HRQoL endpoints
Standardised HRQoL measures were reported in only
 of 23 SPCs (22%). The G-BA accepted applied instru-
ents as relevant to patients in 15 of 23 medicines (65%).
owever, only in 5 of those 15 medicines (33%) were the
peciﬁc analyses provided by the pharmaceutical manufac-
urer considered by the G-BA, with only 2 of those 5 (40%)
ndicating an additional beneﬁt. The 3 remaining medicines
60%) showed no signiﬁcant difference to the AC (Table 4).
Twenty-six of the 29 HRQoL measures (90%) used by
anufacturers were accepted by the G-BA (Table 4). The
European Organisation for Research and Treatment of Can-
er Quality of Life Questionnaire’ (EORTC QLQ-30) [13,14]
as accepted in 8 EBAs, and the module for multiple
yeloma (EORTC QLQ-MY20) was accepted in the EBA
f pomalidomide. Other cancer-speciﬁc questionnaires,
uch as the indication-speciﬁc modules of the ‘Functional
ssessment of Cancer Therapy’ (FACT) questionnaires,
ere accepted in 6 EBAs (Table 4). The general ‘European
uality of Life 5-Dimensions questionnaire’ was accepted
n 7 EBAs. Appropriate instruments to assess HRQoL exist.
owever, the analysis of HRQoL was only considered in 5
edicines. Reasons therefore are stated in Table 4. Minor
ariability between questionnaires led to some exclusions
rom the respective evaluations; for example, the exclu-
ion of a FACT-M subscale in the vemurafenib dossier
11]. The low response rate of the questionnaires was
lso criticised by the G-BA [11]. Differences between the
nvestigated medicines and the AC regarding HRQoL were
dentiﬁed for only 2 medicines (afatinib, crizotinib). The
-BA analysed results of symptoms derived from HRQoL
nstruments in the beneﬁt category morbidity for several
edicines (Table 4).
. Discussion
The comparison of clinical trial endpoints in 23 oncology
edicines accepted by the EMA  and subsequently included
n the SPC and considered as relevant to patients by the
-BA in the beneﬁt assessment revealed:
) a high level of agreement between the two authorities
with regard to endpoints covering the beneﬁt category
of mortality;
) lack of alignment between the EMA  and the G-BA related
to morbidity endpoints such as PFS and RR;
) poor reﬂection of standardised HRQoL measures in SPCs;
a high level of acceptance of HRQoL instruments by the
G-BA, but poor contribution of HRQoL results to the ﬁnal
beneﬁt decision by the G-BA.These inconsistencies beg the question whether differ-
nt endpoints in marketing authorisation versus beneﬁt
ssessment are justiﬁed. Whereas the aims of both eval-
ations differ (EMA–beneﬁt; G-BA–additional beneﬁt),18 (2014) 242–254 251
marketing authorisation and reimbursement are based on
the same value dimensions. Furthermore, clinical data from
the same pivotal studies are used as the base for EMA as
well as G-BA decisions. In order to take the varying aims of
both approaches into account, different comparators may
be considered. However, the identical endpoints should
form the base for both evaluations.
4.1. Inclusion of (co-)primary endpoints
Marketing authorisation of oncology medicines has
been based predominantly on single primary endpoints
assessing mortality (i.e. OS) and morbidity (e.g. PFS,
response) and has been generally consistent with guidance
on acceptable oncology endpoints (Table 1) [8]. In contrast,
we found less consistency between general guidance from
the G-BA on beneﬁt categories and the reality observed in
EBAs of oncology medicines. Whilst the guidance states
that the beneﬁt categories of mortality, morbidity and
HRQoL should all be considered [2–4], our results indi-
cate greater willingness to consider mortality endpoints
(i.e. OS) to support additional therapeutic beneﬁt. Overall,
only about 50% of primary endpoints of marketing autho-
risation programmes of the 23 evaluated medicines were
included by the G-BA in their value decision.
4.2. Mortality is the preferred outcome beneﬁt category
in EBAs of oncology medicines
We  found that mortality was  recognised as the preferred
outcome beneﬁt category to form the base for G-BA deci-
sions in oncology, whereas additional beneﬁts in morbidity
and HRQoL were conﬁrmed less frequently.
OS may  not always be appropriate as a single endpoint
for evaluating additional beneﬁt. For diseases with a high
cure rate or slow chronic course, a long period of assess-
ment is required to enable a valid evaluation of OS [15,16].
The measurement of OS can also be skewed by the effects
of subsequent therapies [15]. For example, difﬁculties in
showing an effect on OS were evident in breast [17] and
lung cancer [15]. Furthermore, cross-over design allow-
ing patients to cross-over into the active treatment arm,
demanded by ethics committees, caregivers and patients,
dilutes the treatment effect estimate of OS [16], downgrad-
ing the potential extent of additional beneﬁt evaluated in
the EBA. For example, 12 of 13 remissions in the control
group of the vandetanib registration trial occurred during
the use of vandetanib in the open-label phase [11]. In the
case of crizotinib, 62% of patients switched to the effective
treatment, resulting in a non-signiﬁcant effect in mortal-
ity [11]. In addition, cross-over had a substantial effect on
OS estimates in the trial of vemurafenib (hazard ratio [HR]
before cross-over 0.37 versus HR after cross-over 0.44 and
0.62 [3 and 9 months after study cut-off, respectively]) [11].
Disregarding the (co-)primary endpoints from regula-
tory clinical trials has an additional drawback in evaluation
of beneﬁt. Clinical studies are statistically powered for the
(co-)primary endpoints, however not for other endpoints
in the trial. If the (co-)primary endpoints are disregarded
for one reason or another, the beneﬁt assessment may
be based on underpowered analyses. Even if statistically
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Table 4
Inclusion of HRQoL instruments and analysis of cancer medicines in G-BA value decision (aﬂibercept, brentuximab vedotin, eribulin, pixantrone, ponatinib, tegafur/glimeracil/oteracil did not provide information
regarding standardised instruments and therefore are excluded from this table).
Summary  of  Product
Characteristics
Manufacturer’s  EBA  dossier  G-BA  decisiona
Medicine  Reported  instruments  Reported  instruments  Reported  results  Instruments  Analysis
Abiraterone  acetate FACT-P  FACT-P  Signiﬁcant  improvement Yes  No  –  clinical  relevance  uncertain
Afatinib  EORTC  QLQ-C30  EORTC  QLQ-C30  Signiﬁcant  improvements  Yes  (also  evaluated  in  morbidity)  Yes,  but  high  potential  for  bias
EORTC  QLQ-LC13 EQ-5D  Signiﬁcant  improvements Yes  No  –  no  results  for  subscales  and  patient  subgroups
provided
Axitinib  None  FKSI-15  No  signiﬁcant  difference  Yes  Yes,  but  no  signiﬁcant  difference
FKSI-DRS  No  signiﬁcant  difference Yes  (but  evaluated  in  morbidity) No  –  only  symptoms  evaluated,  therefore  morbidity
Bosutinib  None  FACT-LEU  Signiﬁcant  improvement  Yes  No  –  no  relevant  data  provided
EQ-5D  Signiﬁcant  improvement Yes  No  –  no  relevant  data  provided
Cabazitaxel  PPI  score  PPI  score  No  signiﬁcant  difference  Yes  (but  evaluated  in  morbidity)  No  –  analysing  pain  alone  not  sufﬁcient  for
evaluation  of  HRQoL
Analgesic  score  No  signiﬁcant  difference  No  –  validity  uncertain  n/a
Crizotinib  None  EORTC  QLQ-C30  Signiﬁcant  improvement  Yes  (also  evaluated  in  morbidity)  Yes
EQ-5D  Signiﬁcant  improvement Yes  No  –  patient  number  too  small  (40%  of  enrolled)
Dabrafenib  None  EORTC  QLQ-C30  No  ITC  provided  Yes  (also  evaluated  in  morbidity)  No  –  no  relevant  data  provided
EQ-5D  No  ITC  provided Yes
Decitabine  None  EORTC  QLQ-C30  No  signiﬁcant  difference,  positive  trend  Yes  No  –  small  rate  of  return,  no  speciﬁc  validation  for
AML,  methodological  concerns
Enzalutamide  None  FACT-P  Signiﬁcant  Yes  (single  item  evaluated  in  morbidity)  No  –  biased  data  (marked  difference  in  response
rates)
EQ-5D  Positive  trend  (not  signiﬁcant)  Yes  No  –  introduced  after  study  start,  not  used  in  all
countries
Ipilimumab  None  EORTC  QLQ-C30  No  signiﬁcant  difference  (except
obstipation)
Yes  Yes,  but  only  at  12  weeks  (no  signiﬁcant
differences);  at  24  weeks  rate  of  return  too  low
Pertuzumab  FACT-B  FACT-B  No  difference  No  –  non-validated  version  used  n/a
Pomalidomide  None  EORTC  QLQ-C30  No  signiﬁcant  differences  in  13  out  of  15
scales
Yes  Yes,  but  no  signiﬁcant  difference
EORTC  QLQ-MY20  No  signiﬁcant  difference  Yes  Yes,  but  no  signiﬁcant  difference
EQ-5D  No  signiﬁcant  difference  Yes  Yes,  but  no  signiﬁcant  difference
Regorafenib  None  EORTC  QLQ-C30  No  signiﬁcant  difference  Yes  No  –  rate  of  return  too  low
EQ-5D  No  data  presented Yes
Ruxolitinib  EORTC  QLQ-C30  EORTC  QLQ-C30  Signiﬁcant  improvement  Yes  No  –  low  return  rate;  imbalance  between  study
groups  at  baseline;  methodological  concerns
FACT-Lym  No  statistical  evaluation  Yes  No  –  methodological  concerns
ECOG  performance
status
Positive  trend  (not  signiﬁcant)  Yes  (but  evaluated  in  morbidity)  No  –  captures  functional  status,  not  HRQoL
Vandetanib  None  FACT-G  No  statistical  evaluation  Yes  No  –  explorative  evaluation  and  descriptive  data  only
Vemurafenib  None  FACT-M  No  difference  No  –  manufacturer  used  shortened
questionnaire  (surgical  treatment  omitted);  no
valid  calculations  for  total  score  possible
n/a
Vismodegib  None  SF-36  Results  for  single  arm  study  reported;  no
historical  control  values  available
Yes  No  –  no  historical  control  values  available;  rate  of
return  too  low  at  end  of  study
AML, acute myeloid leukaemia; EBA, early beneﬁt assessment; ECOG, Eastern Cooperative Oncology Group; EORTC QLQ, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
(C,  cancer; LC, lung cancer; MY,  multiple myeloma); EQ-5D, European Quality of Life 5-Dimensions questionnaire; FACT, Functional Assessment of Cancer Therapy (B, breast cancer; G, general; Lym, lymphoma;
LEU,  leukaemia; M,  melanoma; P, prostate cancer); FKSI, Functional Assessment of Cancer Therapy-Kidney Symptom Index (kidney cancer; DRS, disease-related symptoms); G-BA, Federal Joint Committee;
HRQoL,  health-related quality of life; n/a, not assessed; PPI, present pain intensity; ITC, indirect treatment comparison.
a In case of different subgroups/indications for a medicine, the best subgroup/indication assessment is shown. Inclusion means that the G-BA in principle accepted endpoints as valid; however, it does not
mean  that the data led to a favourable beneﬁt assessment. Material of the G-BA decision (decision, rationale ‘Tragende Gründe’ and summary ‘Zusammenfassende Dokumentation’ [if available]) was used as a
data  source.
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igniﬁcant, the conﬁdence intervals in such cases are
enerally wider and the evaluations (based on conﬁdence
imits) not as good.
.3. Major discrepancies in consideration of morbidity
ndpoints between EMA  and G-BA
Guidance on acceptable endpoints and their assignment
s required to promote innovation and reduce healthcare
urden. Measurable and meaningful endpoints for morbid-
ty that are considered relevant to patients by both EMA  and
-BA need to be deﬁned.
While widely accepted in market authorisation and
ell established as an endpoint in clinical trials through
ecades of extensive systematic evaluation [8], PFS was
ot regarded as patient-relevant by the G-BA in their value
ecision. Consideration of endpoints by reimbursement
odies should not be solely based on their acceptance
y regulatory authorities. However, it is hard to believe
hat almost all morbidity-related primary endpoints within
lobal trial programmes and approved by ethics commit-
ees were considered not relevant to patients by G-BA. For
xample, in the assessment of axitinib for renal cell carci-
oma, PFS was used to assess the delay in onset of pain and
voidance of complications by detecting spine metastases
ith imaging diagnostics. In the interest of the patient,
t is essential to detect these spine metastases before the
ain becomes symptomatic due to a breakthrough of the
pine. In pertuzumab, the manufacturer suggested that a
hange of the therapeutic regimen after progression should
e considered relevant to patients [11]. However, G-BA did
ot reﬂect this argument in the related beneﬁt decision. If
-BA suggests that progression captured by imaging tech-
iques is not sufﬁciently relevant to patients, clariﬁcation
s required as to which additional elements (e.g. change of
herapeutic regimen after progress) are needed to support
atient-relevance for PFS. As divergent opinions regarding
FS are acknowledged in the G-BA decisions (‘Tragende
ründe’) of several oncology medicines, the reasoning
ehind such disagreement should be made transparent and
 public scientiﬁc debate is required.
Additionally, an analysis of patient-relevant end-
oints in oncology proved the suitability of survival of
atients without their disease getting worse (i.e. PFS)
s a morbidity-related, separate endpoint [7]. Regarding
roblems and complications of a disease, a signiﬁcant
mprovement of PFS with acceptable side effects was seen
s a valid, clinically relevant, patient-relevant beneﬁt in
erms of morbidity, especially in maintenance treatment
nd palliative situations [7].
In reimbursement evaluations, acceptability of PFS
aries in different EU countries and is done on a case-by-
ase basis [18]. In contrast to the German G-BA, British
nd French HTA bodies (the National Institute for Health
nd Care Excellence [NICE] and the Haute Autorité de
anté [HAS], respectively) have taken PFS into account
or their assessments [19,20]. NICE considered the results
btained for PFS in the evaluation of abiraterone acetate,
emurafenib and cabazitaxel, and stated PFS and OS as
atient-relevant endpoints in the assessment of imatinib
19]. HAS awarded an additional beneﬁt (‘amélioration18 (2014) 242–254 253
du service médical rendu’) to vemurafenib based on con-
sideration of OS and PFS [20]. Moreover, PFS was listed
as a clinical patient-relevant endpoint in an analysis of
international HTAs [21]. The European Network for Health
Technology Assessments (EUnetHTA) supported the rele-
vance of PFS as a self-standing endpoint [22]. In the ﬁeld
of oncology, especially when there is a high unmet need
and/or no available therapeutic alternative, PFS is a relevant
endpoint for both regulatory and reimbursement evalu-
ations. Morbidity can be regarded differently depending
on the indication and deﬁnition. The rationale for differ-
ent views must undergo scientiﬁc (and public) discussion.
The acceptability of PFS might also depend on disease stage
(e.g. adjuvant setting: PFS acceptable; metastatic setting:
PFS alone insufﬁcient) [18,22].
While frequently used in marketing authorisation, RR
is not well reﬂected in G-BA assessments. Whereas ORR is
not considered by the G-BA in any EBA, CR if related to a
decrease in patient symptoms, was included in the G-BA
decision of 2 medicines. As an advantage compared to OS,
ORR and CR can be assessed earlier and in smaller studies.
Although cytogenic, haematologic and molecular response
to treatment is not symptomatic in patients, G-BA in gen-
eral considered their patient relevance in the context of
the morbidity category. However, these endpoints were not
ultimately used for the G-BA decision.
Improvements in disease severity and pain were
accepted by the G-BA as patient-relevant morbidity end-
points, showing a positive effect on the patient. However,
the endpoints are not assigned rigorously to one of the
three beneﬁt categories. For example, the G-BA assessed
symptoms and tolerability derived from HRQoL instru-
ments or the safety evaluation, respectively, as morbidity
endpoints in several EBAs.
4.4. Methodological standards for HRQoL assessments in
clinical trials in oncology are immature
Appropriate instruments to assess HRQoL in oncology
are already available [13,14,23,24]. For example, EORTC
QLQ [13,14] and FACT questionnaires [23,24] are widely
established in clinical evaluations and have already been
accepted by the G-BA. However, the lack of success of
HRQoL data to support G-BA decisions highlights a number
of methodological challenges:
i) The generation of a hypothesis is particularly chal-
lenging with HRQoL. A good result in HRQoL, paired
with higher OS, generally indicates a major success.
It remains unclear if an increase in HRQoL should be
compulsory for a positive G-BA opinion, or whether a
stable HRQoL level already generates an additional ben-
eﬁt, especially if accompanied by additional life time or,
in spite of additional medication, in the case of severe
disease.
ii) A term frequently used in the context of HRQoL is
patient-reported outcomes (PRO). PRO measure is an
umbrella term for the capturing of health status, symp-
toms, HRQoL, adherence to treatment, satisfaction with
treatment, etc. with the emphasis placed upon the
patient’s judgement. Differentiation and clariﬁcation of
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the overlap and differences of the two concepts are
required.
iii) Furthermore, there is the challenge of missing data with
HRQoL instruments, in particular, if frequent assess-
ments during clinical trials are needed.
5. Conclusions
Our ﬁndings highlight the differences in the approaches
of regulatory agencies and the German G-BA with regard
to inclusion of endpoints in their ﬁnal valuation and list-
ing for marketing authorisation (EMA) and reimbursement
(G-BA) of oncology medicines. Endpoints covering the ben-
eﬁt category of mortality are widely accepted by both EMA
and G-BA. Well established and clinically relevant mor-
bidity endpoints are accepted by the EMA, however are
mostly excluded by the G-BA from their value decision.
HRQoL endpoints are poorly reﬂected in both SPCs and ben-
eﬁt appraisals by the G-BA. The applicability of methods
used for beneﬁt assessments to HRQoL differs from that of
mortality and morbidity. This subject also requires further
scientiﬁc discussion.
To promote innovation in a high cost, high health-
care burden area such as oncology, we would suggest
more speciﬁc guidance and authority input on acceptable,
patient-relevant endpoints for key oncological conditions,
especially in morbidity. A closer alignment of regulatory
and HTA requirements for oncology endpoints is desper-
ately needed. As the usefulness of particular endpoints
varies according to tumour entity and disease stage, out-
come measures should ideally take into account the speciﬁc
patient population and disease condition and be weighted
accordingly.
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